Reimbursed Care Access in Serbia

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. This reflects the application of Serbia’s law on controlled/psychotropic substances which lists psychotropic compounds and limits therapeutic use to tightly regulated circumstances (research or exceptional therapeutic decisions governed by the Ministry of Health and implementing regulations). # #.

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Possession, production, distribution and use of MDMA are criminalised under the Serbian framework; any therapeutic use would require an authorised clinical trial and Ministry of Health approvals. # #.

Esketamine (marketed as SPRAVATO® in jurisdictions where it is authorised) has an established regulatory pathway and restricted medical indication internationally for treatment‑resistant major depressive disorder (TRD) — e.g., it holds a European marketing authorisation from the EMA for TRD under a controlled distribution/monitoring framework. #.

However, there is no evidence of a Serbian national marketing authorisation or inclusion of esketamine in Serbian publicly reimbursed mental‑health formularies in available public records; therefore esketamine is not routinely available or reimbursed in Serbia. Clinicians in Serbia do use ketamine for anaesthesia/analgesia (see ketamine entry) but access to pharmaceutical esketamine for psychiatric indications in Serbia would require either (a) a formal clinical trial authorised by the Ministry of Health / competent ethics committees or (b) importation under special‑use/compassionate‑use procedures if allowed case‑by‑case — neither of which constitutes routine, reimbursed provision. For the EMA authorisation and product information see the EMA EPAR. For Serbia’s controlled‑substances regulatory framework and the legal constraints on psychotropic agents see national law analyses. # #.

Ketamine is a legally available medicinal product in Serbia and is widely used within the Serbian healthcare system primarily as an anaesthetic and analgesic agent in hospitals, emergency medicine and procedural sedation. Serbian anaesthesiology literature and clinical practice guidelines reflect routine ketamine use for induction/maintenance of anaesthesia, analgesic adjuvant roles and in acute care settings; use in psychiatry for depression is off‑label and not part of a nationally standardised, publicly reimbursed psychiatric treatment pathway. # #.

Regulatory and reimbursement context: ketamine as an authorised medicinal product is governed in Serbia by the medicines regulatory framework and is distributed to hospitals and clinics for labelled anaesthetic/analgesic indications; reimbursement and procurement are handled via standard hospital procurement and the Ministry of Health / national health insurance mechanisms for hospital medicines (i.e., ketamine used in inpatient care is provided through hospital budgets and procurement rather than via an outpatient reimbursed psychiatric drug programme). There is no general outpatient, reimbursed psychiatric ketamine programme for TRD financed by the national health insurance. Any psychiatric/off‑label use (e.g., for treatment‑resistant depression) would require local institutional governance (hospital formularies, ethics committee review for off‑label protocols) and is typically delivered in private clinics or tertiary centres on a case‑by‑case basis; such usage is not universally reimbursed by public health insurance and is predominantly private or self‑pay when offered outside inpatient anaesthesia contexts. # #.

Practical notes and regional nuance: because ketamine is a standard anaesthetic, availability in Serbia is broad across public hospitals for surgical and emergency indications; conversely, structured psychiatric ketamine services (infusion clinics, outpatient programs) are not a standard, reimbursed component of Serbia’s national mental‑health formularies and tend to be provided privately or within research settings when offered for depression.

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. This prohibition generally extends to DMT in all forms (synthetic DMT and DMT‑containing preparations such as ayahuasca) under Serbia’s psychotropic/narcotics legislation; possession or distribution outside authorised research carries criminal penalties. # #.

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Like other DMT‑class tryptamines, 5‑MeO‑DMT is subject to criminal prohibition for production, possession and distribution in Serbia outside of authorised research. # #.

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognised ibogaine treatment pathway in Serbia; the compound is not authorised for medical use and any administration would be limited to formally authorised clinical trials. # #.

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Because ayahuasca contains DMT, it falls under the same controls as DMT; ceremonial/religious claims do not create a recognised legal exemption in Serbia and possession/importation may incur criminal sanctions unless explicitly authorised in the context of a sanctioned research protocol. # #.

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and mescaline‑containing cacti preparations) are controlled and are not part of Serbian medical practice except within authorised research. # #.

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. The class of synthetic phenethylamine psychedelics (2C‑series) is covered by Serbia’s psychotropic controls and is illegal to possess, produce or distribute outside formal research. # #.